Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN® clinical evidence study in Portugal

Carneiro, Angela; Meireles, Angelina; Castro Sousa, João Paulo; Teixeira, Carla

Publication

Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN® clinical evidence study in Portugal

2020Journal article

dc.contributor.author	Carneiro, Angela
dc.contributor.author	Meireles, Angelina
dc.contributor.author	Castro Sousa, João Paulo
dc.contributor.author	Teixeira, Carla
dc.date.accessioned	2022-07-14T13:59:27Z
dc.date.available	2022-07-14T13:59:27Z
dc.date.issued	2020
dc.description.abstract	Introduction: The ILUVIEN® (fluocinolone acetonide) Clinical Evidence in Portugal (ICE-PT) study is a retrospective, multicenter, observational study evaluating the effectiveness and safety of the FAc implant in patients with diabetic macular edema. Methods: Patients included in this study had received the 0.2 µg/day fluocinolone acetonide implant for the treatment of diabetic macular edema and had measurements of visual acuity and retinal thickness assessed by optical coherence tomography for at least 12 months pre- and post-fluocinolone acetonide implant administration, with ⩾2 follow-up visits. Outcomes measured included visual acuity, central foveal thickness, and intraocular pressure. Results: There was a significant increase in mean visual acuity compared with baseline at 3, 6, 9, and 12 months post-fluocinolone acetonide in both the overall study population and the pseudophakic subgroup (p < 0.05 at all time points in both groups). A significant reduction in mean central foveal thickness compared with baseline was seen in the overall study population at 3, 6, 9, and 12 months post-fluocinolone acetonide (p < 0.05 at all time points). At 12-month post-fluocinolone acetonide, a small but significant intraocular pressure increase of 1.0 mmHg was seen in the overall study population. Conclusion: The results of this analysis show that switching from the current standard of care to the fluocinolone acetonide implant leads to beneficial effects in terms of vision and retinal structure in patients with diabetic macular edema and that patients benefited from FAc implant administration, regardless of lens status.	pt_PT
dc.description.sponsorship	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Alimera Sciences, the manufacturer of Iluvien 190 mg intravitreal implant, who designed the study and commented on the manuscript. Medical writing assistance was provided by Helios Medical Communications, Alderley Edge, Cheshire, UK and supported by Alimera Sciences.	pt_PT
dc.description.version	info:eu-repo/semantics/publishedVersion	pt_PT
dc.identifier.citation	Carneiro A, Meireles A, Castro Sousa JP, Teixeira C. Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN® clinical evidence study in Portugal. Ther Adv Ophthalmol. 2020;12:2515841420917768. doi:10.1177/2515841420917768	pt_PT
dc.identifier.doi	10.1177/2515841420917768	pt_PT
dc.identifier.issn	2515-8414
dc.identifier.uri	http://hdl.handle.net/10400.16/2723
dc.language.iso	eng	pt_PT
dc.peerreviewed	yes	pt_PT
dc.publisher	SAGE Publications	pt_PT
dc.relation.publisherversion	https://journals.sagepub.com/doi/10.1177/2515841420917768?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	pt_PT
dc.rights.uri	http://creativecommons.org/licenses/by-nc/4.0/	pt_PT
dc.subject	Portugal	pt_PT
dc.subject	clinical evidence	pt_PT
dc.subject	diabetic macular edema	pt_PT
dc.subject	fluocinolone acetonide intravitreal implant	pt_PT
dc.subject	visual acuity	pt_PT
dc.title	Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN® clinical evidence study in Portugal	pt_PT
dc.type	journal article
dspace.entity.type	Publication
oaire.citation.conferencePlace	United States of America	pt_PT
oaire.citation.startPage	251584142091776	pt_PT
oaire.citation.title	Therapeutic Advances in Ophthalmology	pt_PT
oaire.citation.volume	12	pt_PT
person.familyName	Meireles
person.givenName	Angelina
person.identifier.orcid	0000-0001-9148-2786
rcaap.rights	openAccess	pt_PT
rcaap.type	article	pt_PT
relation.isAuthorOfPublication	8832627a-5103-43bb-a479-6556c8b18d44
relation.isAuthorOfPublication.latestForDiscovery	8832627a-5103-43bb-a479-6556c8b18d44